Daiichi Sankyo, Inc. has reached a civil settlement with the US Government, as well as participating states to conclude a Federal investigation related to certain types of speaker programmes related to Azor, Benicar, Benicar HCT, Welchol and Tribenzor.

Under the agreement, the company has agreed to pay approximately $39 million, plus fees and costs, and has entered into a Corporate Integrity Agreement with the Office of Inspector General for the US Department of Health and Human Services.

The settlement involves claims regarding Physician Opinion & Discussion programmes during the period from January 1, 2005, through March 31, 2011, and other speaker programmes during the period from January 1, 2004, through February 4, 2011.

“We are pleased to have finalised these agreements and remain focused on our core mission of helping people live healthy and meaningful lives,” said Ken Keller, president, US Commercial, Daiichi Sankyo, Inc. “We are committed to being an ethical, trusted and respected company, and constantly improving how we operate is part of our culture. As part of our compliance programme, we continue to review and strengthen our policies, procedures and processes to ensure compliance with applicable laws, regulations and industry standards, and to meet our own high ethical standards.”

Daiichi Sankyo, Inc. cooperated with investigators at all times throughout the investigative process.